Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hainan Shuangcheng Pharmaceutical Co., Ltd. is a high-tech enterprise established in 2000, specializing in the production, sales, and research and development of chemically synthesized peptide drugs. The company has formed a complete set of mature technical process systems in the synthesis, purification, analysis, quality assurance, activity determination, and formulation process of chemically synthesized peptide drugs. The company was listed on the Shenzhen Stock Exchange on August 8, 2012, with the stock name "Shuangcheng Pharmaceutical" and the stock code "002693". The company has rich experience in the research and development, registration, production, and marketing of chemically synthesized peptide drugs. It has successfully developed multiple chemically synthesized peptide drugs and 20 other various therapeutic drugs, among which peptide drugs mainly include thymosin for injection ("Kitai"), a type of immune enhancing drug, Mainly used for the treatment of various types of liver diseases, tumors, geriatric and infectious diseases, as well as the improvement of body immunity. At the same time, this product has passed the quality and efficacy consistency evaluation of injection generic drugs under the national drug supervision and management, and has obtained the marketing license issued by the Italian Drug Administration; Somatostatin for injection is used for the treatment of severe acute esophageal variceal bleeding, severe acute gastric or duodenal ulcer bleeding, diabetes ketoacidosis, etc; Bivalutin for injection has obtained market approval from the US FDA and the National Drug Administration. It is mainly used to prevent ischemic complications before and after angioplasty intervention for unstable angina, and is a first-line medication for direct thrombin inhibitors; Etibatide injection is used in patients with acute coronary syndrome (unstable angina/non ST segment elevation myocardial infarction). Etibatide injection ANDA has been approved for marketing by the US FDA. Since its establishment, Shuangcheng Pharmaceutical has developed rapidly, with a marketing network covering more than 30 provinces, cities, and autonomous regions in mainland China, over 600 cooperative pharmaceutical merchants, and over 10000 hospital terminals covered by its products. Has a stable sales position in the same industry. The company adheres to the corporate philosophy of "the beauty of becoming a person, the wish of becoming oneself". The beauty of becoming a person - conveys health with sincerity, and the wish of becoming oneself - creates brilliance through hard work. While completing the development of the enterprise itself, the company actively fulfills its social responsibility and gives back to society. The company has been repeatedly rated as an A-level tax credit enterprise by the Hainan Provincial State Taxation Bureau and the Hainan Provincial Local Taxation Bureau. In the future, the company's development strategy is to become a leading global supplier of peptide raw materials and a major manufacturer of peptide generic pharmaceutical formulations. |
| Headquarter | Haikou |
| Establish Date | 5/22/2000 |
| Listed Code | 002693.SZ |
| Listed Date | 8/8/2012 |
| Chairman | Wang Chengdong. |
| CEO | Jianming Li. |
| Website | www.shuangchengmed.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
